Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.

Ann Hematol. 2018 Jun 23. doi: 10.1007/s00277-018-3403-9. [Epub ahead of print]

PMID:
29934835
2.

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.

Ann Hematol. 2018 Jun 4. doi: 10.1007/s00277-018-3380-z. [Epub ahead of print] Erratum in: Ann Hematol. 2018 Jun 23;:.

PMID:
29862437
3.

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.

Gampenrieder SP, Rinnerthaler G, Hackl H, Pulverer W, Weinhaeusel A, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Risch A, Greil R.

Theranostics. 2018 Mar 11;8(8):2278-2288. doi: 10.7150/thno.23544. eCollection 2018.

4.

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Melchardt T, Magnes T, Hufnagl C, Thorner AR, Ducar M, Neureiter D, Tränkenschuh W, Klieser E, Gaggl A, Rösch S, Rasp G, Hartmann TN, Pleyer L, Rinnerthaler G, Weiss L, Greil R, Egle A.

Eur J Cancer. 2018 Apr;93:69-78. doi: 10.1016/j.ejca.2018.01.064. Epub 2018 Mar 20.

PMID:
29477794
5.

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.

Huemer F, Weiss L, Faber V, Neureiter D, Egle A, Geissler K, Voskova D, Zebisch A, Burgstaller S, Pichler A, Stauder R, Sperr W, Lang A, Pfeilstöcker M, Machherndl-Spandl S, Stampfl M, Greil R, Pleyer L.

Wien Klin Wochenschr. 2018 Feb;130(3-4):115-125. doi: 10.1007/s00508-018-1315-2. Epub 2018 Jan 30.

6.

Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.

Gutjahr JC, Szenes E, Tschech L, Asslaber D, Schlederer M, Roos S, Yu X, Girbl T, Sternberg C, Egle A, Aberger F, Alon R, Kenner L, Greil R, Orian-Rousseau V, Hartmann TN.

Blood. 2018 Mar 22;131(12):1337-1349. doi: 10.1182/blood-2017-08-802462. Epub 2018 Jan 19.

7.

Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.

Janovska P, Verner J, Kohoutek J, Bryjova L, Gregorova M, Dzimkova M, Skabrahova H, Radaszkiewicz T, Ovesna P, Vondalova Blanarova O, Nemcova T, Hoferova Z, Vasickova K, Smyckova L, Egle A, Pavlova S, Poppova L, Plevova K, Pospisilova S, Bryja V.

Blood. 2018 Mar 15;131(11):1206-1218. doi: 10.1182/blood-2017-05-786947. Epub 2018 Jan 9.

PMID:
29317454
8.

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.

Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, Gutjahr JC, Pleyer L, Egle A, Hartmann TN, Greil R, Geisberger R.

Oncoimmunology. 2017 Sep 21;7(1):e1371399. doi: 10.1080/2162402X.2017.1371399. eCollection 2017.

9.

Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017.

Magnes T, Egle A, Greil R, Melchardt T.

Memo. 2017;10(4):220-223. doi: 10.1007/s12254-017-0358-9. Epub 2017 Oct 20. Review.

10.

The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle A.

Pharmacogenomics J. 2018 May 22;18(3):474-479. doi: 10.1038/tpj.2017.37. Epub 2017 Jul 18.

PMID:
28719596
11.

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.

Magnes T, Melchardt T, Weiss L, Mittermair C, Neureiter D, Klieser E, Gampenrieder S, Moser G, Gaggl A, Greil R, Egle A.

PLoS One. 2017 Jul 7;12(7):e0180995. doi: 10.1371/journal.pone.0180995. eCollection 2017.

12.

Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.

Leisch M, Weiss L, Lindlbauer N, Jungbauer C, Egle A, Rohde E, Greil R, Grabmer C, Pleyer L.

Leuk Res. 2017 Aug;59:12-19. doi: 10.1016/j.leukres.2017.05.006. Epub 2017 May 9.

13.

Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.

Weiss L, Melchardt T, Egle A, Hopfinger G, Hackl H, Greil R, Barth J, Rummel M.

Ann Hematol. 2017 Jul;96(7):1155-1162. doi: 10.1007/s00277-017-3003-0. Epub 2017 Apr 30.

14.

Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of memo.

Egle A.

Memo. 2017;10(1):8-12. doi: 10.1007/s12254-017-0318-4. Epub 2017 Feb 27. Review.

15.

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.

Kazianka L, Drucker C, Skrabs C, Thomas W, Melchardt T, Struve S, Bergmann M, Staber PB, Porpaczy E, Einberger C, Heinz M, Hauswirth A, Raderer M, Pabinger I, Thalhammer R, Egle A, Wendtner CM, Follows G, Hoermann G, Quehenberger P, Jilma B, Jaeger U.

Leukemia. 2017 May;31(5):1117-1122. doi: 10.1038/leu.2016.316. Epub 2016 Nov 2.

16.

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M; AGMT Investigators.

Blood. 2017 Jan 19;129(3):383-385. doi: 10.1182/blood-2016-06-720599. Epub 2016 Nov 22. No abstract available.

17.

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

Huemer F, Dejaco M, Grabmer C, Melchardt T, Neureiter D, Mayer G, Egle A, Greil R, Weiss L.

Wien Klin Wochenschr. 2017 Feb;129(3-4):141-144. doi: 10.1007/s00508-016-1124-4.

18.

NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.

Prochazka KT, Melchardt T, Posch F, Schlick K, Deutsch A, Beham-Schmid C, Weiss L, Gary T, Neureiter D, Klieser E, Greil R, Neumeister P, Egle A, Pichler M.

Br J Cancer. 2016 Nov 8;115(10):1264-1272. doi: 10.1038/bjc.2016.325. Epub 2016 Oct 20.

19.

CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.

Zaborsky N, Gassner FJ, Asslaber D, Reinthaler P, Denk U, Flenady S, Hofbauer JP, Danner B, Rebhandl S, Harrer A, Geisberger R, Greil R, Egle A.

Oncotarget. 2016 Aug 2;7(31):49459-49469. doi: 10.18632/oncotarget.10372.

20.

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A.

Lancet Haematol. 2016 Jul;3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X. Epub 2016 Jun 16.

PMID:
27374465
21.

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.

Melchardt T, Hufnagl C, Weinstock DM, Kopp N, Neureiter D, Tränkenschuh W, Hackl H, Weiss L, Rinnerthaler G, Hartmann TN, Greil R, Weigert O, Egle A.

Oncotarget. 2016 Aug 9;7(32):51494-51502. doi: 10.18632/oncotarget.9860.

22.

Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.

Magnes T, Melchardt T, Weiss L, Hufnagl C, Greil R, Egle A.

J Clin Oncol. 2016 Jul 10;34(20):2433-4. doi: 10.1200/JCO.2016.66.6057. Epub 2016 May 9. No abstract available.

PMID:
27161962
23.

Bcl-2 proteins in development, health, and disease of the hematopoietic system.

Kollek M, Müller A, Egle A, Erlacher M.

FEBS J. 2016 Aug;283(15):2779-810. doi: 10.1111/febs.13683. Epub 2016 Mar 21. Review.

24.

ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.

Krenn PW, Hofbauer SW, Pucher S, Hutterer E, Hinterseer E, Denk U, Asslaber D, Ganghammer S, Sternberg C, Neureiter D, Aberger F, Wickström SA, Egle A, Greil R, Hartmann TN.

Cancer Res. 2016 Apr 15;76(8):2186-96. doi: 10.1158/0008-5472.CAN-15-3379. Epub 2016 Feb 2.

25.

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.

Huemer F, Melchardt T, Tränkenschuh W, Neureiter D, Moser G, Magnes T, Weiss L, Schlattau A, Hufnagl C, Ricken G, Höftberger R, Greil R, Egle A.

BMC Cancer. 2015 Dec 22;15:996. doi: 10.1186/s12885-015-2020-4.

26.

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.

Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Schlick K, Huemer F, Deutsch A, Neumeister P, Greil R, Pichler M, Egle A.

J Natl Compr Canc Netw. 2015 Dec;13(12):1501-8.

PMID:
26656519
27.

The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.

Troppan KT, Melchardt T, Wenzl K, Schlick K, Deutsch A, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Tränkenschuh W, Greil R, Neumeister P, Egle A, Pichler M.

J Clin Pathol. 2016 Apr;69(4):326-30. doi: 10.1136/jclinpath-2015-203356. Epub 2015 Dec 7.

PMID:
26644520
28.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P.

Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7.

29.

Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.

Hanna BS, McClanahan F, Yazdanparast H, Zaborsky N, Kalter V, Rößner PM, Benner A, Dürr C, Egle A, Gribben JG, Lichter P, Seiffert M.

Leukemia. 2016 Mar;30(3):570-9. doi: 10.1038/leu.2015.305. Epub 2015 Nov 2.

PMID:
26522085
30.

CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.

Kocher T, Asslaber D, Zaborsky N, Flenady S, Denk U, Reinthaler P, Ablinger M, Geisberger R, Bauer JW, Seiffert M, Hartmann TN, Greil R, Egle A, Piñón Hofbauer J.

Leukemia. 2016 Jun;30(6):1409-13. doi: 10.1038/leu.2015.307. Epub 2015 Nov 2. No abstract available.

31.

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

Melchardt T, Hufnagl C, Magnes T, Weiss L, Hutarew G, Neureiter D, Schlattau A, Moser G, Gaggl A, Tränkenschuh W, Greil R, Egle A.

BMC Cancer. 2015 Oct 16;15:725. doi: 10.1186/s12885-015-1776-x.

32.

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R.

Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.

33.

The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.

Hofbauer SW, Krenn PW, Piñόn Hofbauer J, Pucher S, Asslaber D, Egle A, Hartmann TN, Greil R.

Br J Haematol. 2016 Mar;172(5):815-9. doi: 10.1111/bjh.13542. Epub 2015 Jul 6. No abstract available.

34.

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.

Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, Hartmann TN, Greil R, Geisberger R.

Br J Haematol. 2015 Aug;170(4):515-22. doi: 10.1111/bjh.13467. Epub 2015 May 4.

35.

B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.

Zaborsky N, Holler C, Geisberger R, Asslaber D, Gassner FJ, Egger V, Piñón-Hofbauer J, Kocher T, Hartmann TN, Greil R, Egle A.

Haematologica. 2015 Aug;100(8):e307-10. doi: 10.3324/haematol.2015.124719. Epub 2015 Apr 24. No abstract available.

36.

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.

Ganghammer S, Hutterer E, Hinterseer E, Brachtl G, Asslaber D, Krenn PW, Girbl T, Berghammer P, Geisberger R, Egle A, Zucchetto A, Kruschinski A, Gattei V, Chigaev A, Greil R, Hartmann TN.

Oncotarget. 2015 May 20;6(14):12048-60.

37.

The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.

Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Egle A, Pichler M.

Eur J Haematol. 2015 Dec;95(6):538-44. doi: 10.1111/ejh.12529. Epub 2015 Mar 26.

PMID:
25677782
38.

Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.

Sochalska M, Tuzlak S, Egle A, Villunger A.

FEBS J. 2015 Mar;282(5):834-849. doi: 10.1111/febs.13188. Epub 2015 Jan 23. Review.

39.

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R.

Am J Hematol. 2015 Apr;90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2.

40.

A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.

Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, Hackl H, Greil R, Pichler M, Egle A.

Br J Haematol. 2015 Jan;168(2):239-45. doi: 10.1111/bjh.13116. Epub 2014 Sep 19.

PMID:
25236324
41.

How does lenalidomide target the chronic lymphocytic leukemia microenvironment?

Kater AP, Tonino SH, Egle A, Ramsay AG.

Blood. 2014 Oct 2;124(14):2184-9. doi: 10.1182/blood-2014-05-578286. Epub 2014 Aug 26. Review.

42.

Old and new news in CLL: "It's the pathway, stupid!".

Egle A.

Blood. 2014 Aug 14;124(7):989-90. doi: 10.1182/blood-2014-05-574145. No abstract available.

43.

Kasabach-Merritt phenomenon in hepatic angiosarcoma.

Habringer S, Boekstegers A, Weiss L, Hopfinger G, Meissnitzer T, Melchardt T, Egle A, Greil R.

Br J Haematol. 2014 Dec;167(5):716-8. doi: 10.1111/bjh.13049. Epub 2014 Jul 24. No abstract available.

PMID:
25060176
44.

C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.

Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M.

Br J Cancer. 2014 Jul 8;111(1):55-60. doi: 10.1038/bjc.2014.277. Epub 2014 May 29.

45.

Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.

Melchardt T, Weiss L, Hufnagl C, Neureiter D, Kemmerling R, Morre P, Boekstegers A, Hopfinger G, Auberger J, Steinkirchner S, Pleyer L, Greil R, Egle A.

Leuk Lymphoma. 2015 Feb;56(2):353-60. doi: 10.3109/10428194.2014.916798. Epub 2014 Jun 25.

PMID:
24798743
46.

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.

Melchardt T, Magnes T, Weiss L, Grundbichler M, Strasser M, Hufnagl C, Moik M, Greil R, Egle A.

BMC Complement Altern Med. 2014 Mar 30;14:115. doi: 10.1186/1472-6882-14-115.

47.

Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.

Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, Greil R, Geisberger R.

Haematologica. 2014 May;99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21. No abstract available.

48.

Human immunodeficiency virus type 2 infections in Austria.

Taylor N, Kern JM, Prammer W, Lang A, Haas B, Gisinger M, Zangerle R, Egle A, Greil R, Oberkofler H, Eberle J.

Wien Klin Wochenschr. 2014 Apr;126(7-8):212-6. doi: 10.1007/s00508-013-0493-1. Epub 2014 Jan 18.

PMID:
24442861
49.

Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.

Hopfinger G, Nösslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, Egle A, Greil R.

Ann Hematol. 2014 Mar;93(3):459-62. doi: 10.1007/s00277-014-2009-0. Epub 2014 Jan 18.

PMID:
24441915
50.

Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.

Grössinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, Schmölzer J, Asslaber D, Hainzl S, Neureiter D, Egle A, Piñón-Hofbauer J, Hartmann TN, Greil R, Kerschbaum HH.

Leukemia. 2014 Apr;28(4):954-8. doi: 10.1038/leu.2014.37. Epub 2014 Jan 20. No abstract available.

PMID:
24441290

Supplemental Content

Support Center